Journal: mAbs

Article Title: Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody

doi: 10.1080/19420862.2023.2175312

Figure Lengend Snippet: SE-HPLC chromatogram of a Complex Therapeutic 2 + 1 bsAb. During SE-HPLC of the 2 + 1 CrossMAb after protein A purification, HMW by-products were observed at low abundancy, representing less than 1% of the total area under the curve (AUC). The hypothesized by-products are indicated on the peaks representing HMW variants. Indicated fractions were collected for further analysis.

Article Snippet: Sample injection amounts of 20 μg CrossMAb were used and data acquisition was controlled by Chromeleon software (Thermo Fisher Scientific).

Techniques: Purification

Journal: mAbs

Article Title: Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody

doi: 10.1080/19420862.2023.2175312

Figure Lengend Snippet: Gene reporter assays measuring variant potency. Dose-response curves show the binding of CD3 Fabs to CD3e expressed on JURKAT cells, meant to simulate downstream signaling. The tetravalent control has the highest potency compared to the 2 + 1 CrossMAb control. The HMW1 fraction, thought to contain the tetravalent variant, shows a remarkably similar response as the product control. The dimer (HMW2 fraction) shows a substantially reduced potency.

Article Snippet: Sample injection amounts of 20 μg CrossMAb were used and data acquisition was controlled by Chromeleon software (Thermo Fisher Scientific).

Techniques: Variant Assay, Binding Assay

Journal: mAbs

Article Title: Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody

doi: 10.1080/19420862.2023.2175312

Figure Lengend Snippet: SEC-nMS Analysis of the 2 + 1 CrossMAb Product. The mass of the analyzed product is 197,037.9 Da (cyan diamond). An inset shows the charge deconvoluted spectrum from 6000 to 8500 m/z. Gains and losses of Hex(1) and GlcNAc(1) are annotated by blue and green bars. A small portion of dimer is observed, likely formed through non-covalent interactions during storage.

Article Snippet: Sample injection amounts of 20 μg CrossMAb were used and data acquisition was controlled by Chromeleon software (Thermo Fisher Scientific).

Techniques:

Journal: Pharmaceutics

Article Title: Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

doi: 10.3390/pharmaceutics14112442

Figure Lengend Snippet: Current clinical trials of bsAbs based on mechanism of action in solid malignancies.

Article Snippet: Zenocutuzumab , CrossMab , HER2/HER3 , Solid tumors , 1/2 , NCT02912949 , R , , Merus N.V. (Utrecht, The Netherlands).

Techniques: Clinical Proteomics

Journal: Pharmaceutics

Article Title: Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

doi: 10.3390/pharmaceutics14112442

Figure Lengend Snippet: Current clinical trials of bsAbs based on mechanism of action in solid malignancies.

Article Snippet: Zanidatamab , CrossMab , HER2 , Solid tumors , 1 , NCT02892123 , ANR , , Zymeworks Inc./BeiGene, Ltd. (Vancouver, BC, Canada).

Techniques: Clinical Proteomics